EP 1778269 A2 20070502 - NON-DIABETOGENIC THERAPY USING A 20KDA PLACENTAL GROWTH HORMONE VARIANT
Title (en)
NON-DIABETOGENIC THERAPY USING A 20KDA PLACENTAL GROWTH HORMONE VARIANT
Title (de)
NICHT-DIABETOGENE THERAPIE UNTER VERWENDUNG EINER 20KDA-PLAZENTALVARIANTE DES WACHSTUMSHORMONS
Title (fr)
THERAPIE NON-DIABETOGENIQUE FAISANT INTERVENIR UN VARIANT D'HORMONE DE CROISSANCE PLACENTAIRE 20KDA
Publication
Application
Priority
- US 2005026061 W 20050722
- US 59079404 P 20040723
- US 64946905 P 20050202
Abstract (en)
[origin: WO2006012525A2] Embodiments of the present invention provide improved methods of treating conditions requiring human growth hormone (hGH) therapy, whereby the beneficial effects of hGH such as growth promotion and lipolysis are retained and unwanted properties such as insulin resistance are reduced or eliminated. In particular, embodiments of this invention are directed to methods of treatment whereby the diabetogenic side effects of conventional hGH treatment are reduced. The methods include the use of the growth hormone variant; 20kDa hGH-V in the treatment of conditions that are currently treated with hGH or that have the potential to be treated with hGH.
IPC 8 full level
A61K 38/27 (2006.01); A61K 35/12 (2015.01); A61K 35/76 (2015.01)
CPC (source: EP)
A61K 38/27 (2013.01); A61P 3/00 (2018.01); A61P 3/04 (2018.01); A61P 3/06 (2018.01); A61P 3/10 (2018.01); A61P 5/06 (2018.01); A61P 9/04 (2018.01); A61P 9/10 (2018.01); A61P 9/12 (2018.01); A61P 11/00 (2018.01); A61P 13/12 (2018.01); A61P 15/00 (2018.01); A61P 19/08 (2018.01); A61P 19/10 (2018.01); A61P 25/24 (2018.01); A61P 25/28 (2018.01)
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
DOCDB simple family (publication)
WO 2006012525 A2 20060202; WO 2006012525 A3 20060824; EP 1778269 A2 20070502; EP 1778269 A4 20090923; JP 2008507559 A 20080313
DOCDB simple family (application)
US 2005026061 W 20050722; EP 05799870 A 20050722; JP 2007522809 A 20050722